{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:24Z","timestamp":1792089984794,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00520-026-11274-w","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:53:03Z","timestamp":1790621583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary G-CSF prophylaxis in sacituzumab govitecan\u2013treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort"],"prefix":"10.1007","volume":"34","author":[{"given":"P\u00fcsk\u00fcll\u00fco\u011flu","family":"Miros\u0142awa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polakiewicz-Gilowska","family":"Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konieczna","family":"Aleksandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieni\u0105\u017cek","family":"Ma\u0142gorzata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017bubrowska","family":"Justyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hol\u00e1nek","family":"Milo\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumarov\u00e1","family":"Renata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160tudentov\u00e1","family":"Hana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malej\u010d\u00edkov\u00e1","family":"Miroslava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u0142odzi\u0144ska","family":"Agnieszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winsko-Szcz\u0119snowicz","family":"Karolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisik-Habib","family":"Maja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0119kala","family":"Anika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krej\u010d\u00ed","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160ustr","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kol\u00e1\u0159ov\u00e1","family":"Iveta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielewicz","family":"Iwona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymanik-Resko","family":"Magdalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciszewski","family":"Tomasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru\u0161inov\u00e1","family":"Lenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Czartoryska-Ar\u0142ukowicz","family":"Bogumi\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141acko","family":"Aleksandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pacholczak-Madej","family":"Renata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarz\u0105b","family":"Micha\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biel\u010dikov\u00e1","family":"Zuzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubeczko","family":"Marcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"11274_CR1","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"key":"11274_CR2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2024) Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol 42:1738\u20131744. https:\/\/doi.org\/10.1200\/JCO.23.01409","journal-title":"J Clin Oncol"},{"key":"11274_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K et al (2026) Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med 394:354\u2013366. https:\/\/doi.org\/10.1056\/NEJMoa2508959","journal-title":"N Engl J Med"},{"key":"11274_CR4","unstructured":"National Comprehensive Cancer Network (2026) NCCN clinical practice guidelines in oncology: hematopoietic growth factors. Version 1.2026. National Comprehensive Cancer Network, Plymouth Meeting. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493. Accessed 25 Apr 2026"},{"key":"11274_CR5","unstructured":"National Comprehensive Cancer Network (2026) NCCN clinical practice guidelines in oncology: hematopoietic growth factors. Version 3.2026. National Comprehensive Cancer Network, Plymouth Meeting. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493. Accessed 28 Aug 2026"},{"key":"11274_CR6","unstructured":"European Medicines Agency (2025) Trodelvy: EPAR product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trodelvy. Accessed 15 Aug 2025"},{"key":"11274_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jval.2015.09.2938","volume":"19","author":"C Nordon","year":"2016","unstructured":"Nordon C, Karcher H, Groenwold RHH, Ankarfeldt MZ, Pichler F, Chevrou-Severac H et al (2016) The efficacy-effectiveness gap: historical background and current conceptualization. Value Health 19:75\u201381. https:\/\/doi.org\/10.1016\/j.jval.2015.09.2938","journal-title":"Value Health"},{"key":"11274_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1200\/JCO.19.02035","volume":"38","author":"AJ Templeton","year":"2020","unstructured":"Templeton AJ, Booth CM, Tannock IF (2020) Informing patients about expected outcomes: the efficacy-effectiveness gap. J Clin Oncol 38:1651\u20131654. https:\/\/doi.org\/10.1200\/JCO.19.02035","journal-title":"J Clin Oncol"},{"issue":"3","key":"11274_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag014","volume":"31","author":"M Pieni\u0105\u017cek","year":"2026","unstructured":"Pieni\u0105\u017cek M, Polakiewicz-Gilowska A, \u017bubrowska J, Ru\u0161inov\u00e1 L, \u0160tudentov\u00e1 H, Konieczna A et al (2026) Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe. Oncologist 31(3):oyag014. https:\/\/doi.org\/10.1093\/oncolo\/oyag014","journal-title":"Oncologist"},{"issue":"9","key":"11274_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag281","volume":"31","author":"A Konieczna","year":"2026","unstructured":"Konieczna A, Pieni\u0105\u017cek M, \u017bubrowska J et al (2026) Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study. Oncologist 31(9):oyag281. https:\/\/doi.org\/10.1093\/oncolo\/oyag281","journal-title":"Oncologist"},{"key":"11274_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40487-024-00307-1","volume":"12","author":"M P\u00fcsk\u00fcll\u00fco\u011flu","year":"2024","unstructured":"P\u00fcsk\u00fcll\u00fco\u011flu M, Pieni\u0105\u017cek M, Las-Jankowska M et al (2024) Sacituzumab govitecan for second and subsequent line palliative treatment of patients with triple-negative breast cancer: a Polish real-world multicenter cohort study. Oncol Ther 12:787\u2013801. https:\/\/doi.org\/10.1007\/s40487-024-00307-1","journal-title":"Oncol Ther"},{"key":"11274_CR12","unstructured":"National Cancer Institute (2017) Common terminology criteria for adverse events (CTCAE), Version 5.0. U.S. Department of Health and Human Services"},{"key":"11274_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"11274_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103309","volume":"85","author":"JM P\u00e9rez-Garc\u00eda","year":"2025","unstructured":"P\u00e9rez-Garc\u00eda JM, Gion M, Ruiz-Borrego M et al (2025) Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial. EClinicalMedicine 85:103309. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103309","journal-title":"EClinicalMedicine"},{"key":"11274_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","volume":"208","author":"K Kalinsky","year":"2024","unstructured":"Kalinsky K, Spring L, Yam C et al (2024) Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat 208:203\u2013214. https:\/\/doi.org\/10.1007\/s10549-024-07412-9","journal-title":"Breast Cancer Res Treat"},{"key":"11274_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105308","volume":"10","author":"R Nanda","year":"2025","unstructured":"Nanda R, Yam C, Spring L et al (2025) Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States. ESMO Open 10:105308. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105308","journal-title":"ESMO Open"},{"issue":"16_suppl","key":"11274_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e13145","volume":"43","author":"AR Harisingani","year":"2025","unstructured":"Harisingani AR, Mishra R, Parekh D et al (2025) Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: a real world multicenter study using the TriNetX database. J Clin Oncol 43(16_suppl):e13145. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e13145","journal-title":"J Clin Oncol"},{"key":"11274_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09918-4","volume":"33","author":"M Pieni\u0105\u017cek","year":"2025","unstructured":"Pieni\u0105\u017cek M, Polakiewicz-Gilowska A, Kubeczko M et al (2025) Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights. Support Care Cancer 33:889. https:\/\/doi.org\/10.1007\/s00520-025-09918-4","journal-title":"Support Care Cancer"},{"key":"11274_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00228-025-03949-w","volume":"82","author":"S Liang","year":"2026","unstructured":"Liang S, Liao W, Jiang J et al (2026) Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis. Eur J Clin Pharmacol 82:30. https:\/\/doi.org\/10.1007\/s00228-025-03949-w","journal-title":"Eur J Clin Pharmacol"},{"key":"11274_CR20","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/ijc.70213","volume":"158","author":"S Tunbekici","year":"2026","unstructured":"Tunbekici S, Sahin G, \u00d6n S et al (2026) Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: a multicenter study by the Turkish Oncology Group. Int J Cancer 158:1881\u20131890. https:\/\/doi.org\/10.1002\/ijc.70213","journal-title":"Int J Cancer"},{"key":"11274_CR21","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","volume":"130","author":"D Hanna","year":"2024","unstructured":"Hanna D, Merrick S, Ghose A et al (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer 130:1916\u20131920. https:\/\/doi.org\/10.1038\/s41416-024-02685-9","journal-title":"Br J Cancer"},{"key":"11274_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-026-03346-9","author":"AE Shaaban","year":"2026","unstructured":"Shaaban AE, Jourdain H, Desplas D et al (2026) Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive\/HER2-negative metastatic breast cancer. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-026-03346-9","journal-title":"Br J Cancer"},{"key":"11274_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1717135","volume":"16","author":"A Falc\u00f3n-Gonz\u00e1lez","year":"2026","unstructured":"Falc\u00f3n-Gonz\u00e1lez A, Llabr\u00e9s-Valenti E, Henao-Carrasco F et al (2026) Real-world effectiveness and safety of sacituzumab govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain. Front Oncol 16:1717135. https:\/\/doi.org\/10.3389\/fonc.2026.1717135","journal-title":"Front Oncol"},{"key":"11274_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-026-07971-z","volume":"217","author":"G Tam","year":"2026","unstructured":"Tam G, Waddell D, Freeman JQ et al (2026) Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis. Breast Cancer Res Treat 217:22. https:\/\/doi.org\/10.1007\/s10549-026-07971-z","journal-title":"Breast Cancer Res Treat"},{"key":"11274_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/OP.24.00242","volume":"21","author":"S Alaklabi","year":"2025","unstructured":"Alaklabi S, Roy AM, Zagami P et al (2025) Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer. JCO Oncol Pract 21:620\u2013628. https:\/\/doi.org\/10.1200\/OP.24.00242","journal-title":"JCO Oncol Pract"},{"key":"11274_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231200454","author":"M Reinisch","year":"2023","unstructured":"Reinisch M, Bruzas S, Spoenlein J, Shenoy S, Traut A, Harrach H, Chiari O, Cremer E, Ataseven B, Gubelt L, Kuemmel S (2023) Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359231200454","journal-title":"Ther Adv Med Oncol"},{"key":"11274_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Tolaney SM, Loirat D et al (2022) Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer 8:98. https:\/\/doi.org\/10.1038\/s41523-022-00467-1","journal-title":"NPJ Breast Cancer"},{"key":"11274_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3495","author":"AG Sathe","year":"2025","unstructured":"Sathe AG, Diderichsen PM, Fauchet F et al (2025) Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic triple-negative breast cancer. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.3495","journal-title":"Clin Pharmacol Ther"},{"key":"11274_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00280-025-04823-3","volume":"95","author":"M Pieni\u0105\u017cek","year":"2025","unstructured":"Pieni\u0105\u017cek M, Kubeczko M, Las-Jankowska M et al (2025) Sacituzumab govitecan initial dose reduction in Polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety. Cancer Chemother Pharmacol 95:97. https:\/\/doi.org\/10.1007\/s00280-025-04823-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"11274_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102113","volume":"62","author":"A D\u2019Arienzo","year":"2023","unstructured":"D\u2019Arienzo A, Verrazzo A, Pagliuca M et al (2023) Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine 62:102113. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102113","journal-title":"EClinicalMedicine"},{"key":"11274_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1714638","volume":"16","author":"YX Xu","year":"2026","unstructured":"Xu YX, Shen Q, Lu XF et al (2026) Risk of neutropenia associated with sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis. Front Pharmacol 16:1714638. https:\/\/doi.org\/10.3389\/fphar.2025.1714638","journal-title":"Front Pharmacol"},{"key":"11274_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15020574","volume":"15","author":"F do Pazo-Oubi\u00f1a","year":"2026","unstructured":"do Pazo-Oubi\u00f1a F, del Rosario Garc\u00eda B, Miarons M et al (2026) Impact of UGT1A1*28 allele on the safety and effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: real-world evidence. J Clin Med 15:574. https:\/\/doi.org\/10.3390\/jcm15020574","journal-title":"J Clin Med"},{"key":"11274_CR33","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s J, Punie K, Barrios C et al (2025) Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med 393:1912\u20131925. https:\/\/doi.org\/10.1056\/NEJMoa2511734","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11274-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11274-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11274-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:47Z","timestamp":1792086527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11274-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11274"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11274-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Miros\u0142awa P\u00fcsk\u00fcll\u00fco\u011flu received travel grants and lecture honoraria from AstraZeneca, Roche, Novartis, Eli Lilly, Janssen, Gilead, and Amgen. Anna Polakiewicz-Gilowska received lecture honoraria and travel support from AstraZeneca, Roche, Novartis, Eli Lilly, Swixx Biopharma, Gilead, and Pfizer. Aleksandra Konieczna received travel grants and lecture fees from Pfizer, Novartis, Eli Lilly, MSD, AstraZeneca, and Gilead; and advisory board honoraria from Novartis. Ma\u0142gorzata Pieni\u0105\u017cek received travel support and lecture fees from Pfizer and Novartis; lecture fees from Gilead; and participated in an advisory board for Novartis. Justyna \u017bubrowska received travel grants and lecture fees from MSD, Novartis, and AstraZeneca; and lecture fees from Pfizer, Swixx Biopharma, and Eli Lilly. Milo\u0161 Hol\u00e1nek received travel and conference support from MSD, Gilead, Eli Lilly, and AstraZeneca; received lecture and speaker\u2019s fees from Novartis, Gilead, Eli Lilly, and Teva; and served on advisory boards for AstraZeneca, Eli Lilly, and Gilead. Renata Soumarov\u00e1 received honoraria and support from BMS, AstraZeneca, Pfizer, Novartis, Eli Lilly, MSD, Gilead, Janssen, Astellas, Servier, Accord, and GSK, including advisory board participation. Hana \u0160tudentov\u00e1 received speaker\u2019s fees and conference support from Novartis, MSD, Janssen, Astellas, Pfizer, Richter Gedeon, AstraZeneca, and Ipsen. Miroslava Malej\u010d\u00edkov\u00e1 served as a consultant and expert advisor for Novartis, Amgen, Pfizer, Roche, and AstraZeneca; received honoraria from Novartis, Pfizer, Roche, Teva, and AstraZeneca; and participated in clinical studies sponsored by Novartis, Roche, AstraZeneca, and Pfizer. Agnieszka M\u0142odzi\u0144ska received lecture honoraria from Novartis, Swixx Biopharma, and Gilead; received travel support from Eli Lilly, Pfizer, and Novartis. Karolina Winsko-Szcz\u0119snowicz received travel support and lecture honoraria from Roche, Eli Lilly, Novartis, Pfizer, Gilead, MSD, and Aurovitas. Maja Lisik-Habib received honoraria for lectures from MSD, AstraZeneca, Johnson & Johnson, Roche, BMS, Astellas, Merck, and GSK. Anika P\u0119kala declares no conflicts of interest. Daniel Krej\u010d\u00ed received honoraria, congress fees, and travel support from MSD, AstraZeneca, Novartis, Eli Lilly, Roche, and Pfizer. Jan \u0160ustr received conference support from Gilead and MSD; and speaker\u2019s fees from AstraZeneca and MSD. Iveta Kol\u00e1\u0159ov\u00e1 received honoraria and support from AstraZeneca, Novartis, MSD, Eli Lilly, Roche, Swixx Biopharma, and Gilead, including advisory board participation. Iwona Danielewicz declares no conflicts of interest. Magdalena Szymanik-Resko declares no conflicts of interest. Tomasz Ciszewski received travel grants and lecture fees from Pfizer, Novartis, Eli Lilly, MSD, Roche, Gilead, and AstraZeneca. Lenka Ru\u0161inov\u00e1 declares no conflicts of interest. Bogumi\u0142a Czartoryska-Ar\u0142ukowicz received travel grants and lecture fees from Eli Lilly, Novartis, Pfizer, AstraZeneca, Gilead, and Roche. Aleksandra \u0141acko received honoraria and support from AstraZeneca, Pfizer, Novartis, Eli Lilly, Roche, and Gilead Sciences, including advisory board participation. Renata Pacholczak-Madej received travel grants from Accord and BMS; and lecture fees from AstraZeneca, BMS, MSD, GSK, Novartis, and Roche. Micha\u0142 Jarz\u0105b received conference support from Gilead and Roche; speaker\u2019s fees from Novartis, Roche, Eli Lilly, Pfizer, Teva, Exact Sciences, and Mammotome; and served on advisory boards for Novartis and Pfizer. Zuzana Biel\u010dikov\u00e1 received travel grants and lecture honoraria from AstraZeneca, MSD, Roche, Novartis, Eli Lilly, and Gilead. Marcin Kubeczko served on advisory boards for Novartis; received speaker\u2019s fees and conference support from Novartis, Roche, MSD, Pfizer, Eli Lilly, Teva, Amgen, Swixx Biopharma, AstraZeneca, and Gilead; and participated in clinical trials sponsored by Roche, MSD, Novartis, Seagen, and Gilead.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1030"}}